A key prospective witness in the Ben Roberts-Smith defamation case who has accused the war hero of domestic violence has described “genuine fears” for her mental and physical health if her identity were made public.
Keyboard specialist PKT Technologies has returned for an encore in a six-year long trade mark dispute, appealing a $384,000 judgment against it for violating a trade mark licence agreement with engineer Peter Vogel, inventor of the groundbreaking synthesiser behind some of 80s pop music’s most iconic sounds.
A software-implemented business method could be patentable if programmed into a computer with “some ingenuity”, IP Australia told the Full Federal Court as a landmark appeal between rival tech companies Encompass and Infotrack wrapped up Friday.
Fintech company Encompass has asked the Full Federal Court to take a more “nuanced” approach to software patentability than the one currently held by IP Australia, on the first day of a high-stakes appeal over the patentability of computer-related inventions.
A barrister for the ABC and Fairfax has told the Federal Court that an appeal against the dismissal of their truth defence in the Chau Chak Wing defamation case will have “massive ramifications for mass media”.
A group representing patent and trade mark lawyers is seeking to intervene in a high-stakes appeal over computer software patents.
Decorated war hero Ben Roberts-Smith wants to suppress Fairfax’s defence in a highly contentious defamation case, saying the media company wanted the “scandalous and vexatious” document public so it could report on it.
Generic drug maker Dr Reddy’s Laboratories has reached a settlement with US-based Millennium Pharmaceuticals, agreeing to be restrained from selling a cheap version of cancer drug Velcade in Australia.
A judge has found two patents held by an Eli Lilly & Co. unit for erectile dysfunction drug Cialis are valid and that generic manufacturer Apotex threatened to infringe the patents.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy’s Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.